{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:01:05Z","timestamp":1794448865448,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4974-5","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T11:13:47Z","timestamp":1541416427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells"],"prefix":"10.1186","volume":"18","author":[{"given":"Akihiko","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Kinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Nakatsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoso","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"4974_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519\u201329.","journal-title":"N Engl J Med"},{"key":"4974_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"4974_CR3","unstructured":"NIH Surveillance, Epidemiology, and End Results Program: http:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html (Accessed on 15 Dec 2017)."},{"key":"4974_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) Cancer screening randomized controlled trial. Jama. 2011;305:2295\u2013303.","journal-title":"Jama"},{"key":"4974_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jcp.2004.018077","volume":"58","author":"EL Moss","year":"2005","unstructured":"Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58:308\u201312.","journal-title":"J Clin Pathol"},{"key":"4974_CR6","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4974_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-016-0536-0","volume":"15","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15:48.","journal-title":"Mol Cancer"},{"key":"4974_CR8","doi-asserted-by":"publisher","first-page":"e92921","DOI":"10.1371\/journal.pone.0092921","volume":"9","author":"H Ogata-Kawata","year":"2014","unstructured":"Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9:e92921.","journal-title":"PLoS One"},{"key":"4974_CR9","first-page":"329","volume":"17","author":"M Miyanishi","year":"2007","unstructured":"Miyanishi M, Mandai M, Matsumura N, Yamaguchi K, Hamanishi J, Higuchi T, et al. Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. Oncol Rep. 2007;17:329\u201333.","journal-title":"Oncol Rep"},{"key":"4974_CR10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ijc.22874","volume":"121","author":"HA Kenny","year":"2007","unstructured":"Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007;121:1463\u201372.","journal-title":"Int J Cancer"},{"key":"4974_CR11","doi-asserted-by":"crossref","unstructured":"Lasser C, Eldh M, Lotvall J. Isolation and characterization of RNA-containing exosomes. J Vis Exp. 2012;59:e3037.","DOI":"10.3791\/3037"},{"key":"4974_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/17520363.1.4.513","volume":"1","author":"N Scholler","year":"2007","unstructured":"Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. 2007;1:513\u201323.","journal-title":"Biomark Med"},{"key":"4974_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","volume":"15","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15:78\u201392.","journal-title":"Mol Cancer Res"},{"key":"4974_CR14","doi-asserted-by":"publisher","first-page":"14470","DOI":"10.1038\/ncomms14470","volume":"8","author":"A Yokoi","year":"2017","unstructured":"Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T, et al. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nat Commun. 2017;8:14470.","journal-title":"Nat Commun"},{"key":"4974_CR15","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Yanez-Mo","year":"2015","unstructured":"Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.","journal-title":"J Extracell Vesicles"},{"key":"4974_CR16","first-page":"56","volume":"3","author":"G Hu","year":"2012","unstructured":"Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet. 2012;3:56.","journal-title":"Front Genet"},{"key":"4974_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/br.2016.682","volume":"5","author":"SU Wei","year":"2016","unstructured":"Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016;5:41\u20134.","journal-title":"Biomed Rep"},{"key":"4974_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","volume":"34","author":"S Capriglione","year":"2017","unstructured":"Capriglione S, Luvero D, Plotti F, Terranova C, Montera R, Scaletta G, et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol. 2017;34:164.","journal-title":"Med Oncol"},{"key":"4974_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/1471-2407-12-258","volume":"12","author":"F Li","year":"2012","unstructured":"Li F, Tie R, Chang K, Wang F, Deng S, Lu W, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer. 2012;12:258.","journal-title":"BMC Cancer"},{"key":"4974_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ygyno.2008.04.033","volume":"110","author":"DD Taylor","year":"2008","unstructured":"Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13\u201321.","journal-title":"Gynecol Oncol"},{"key":"4974_CR21","doi-asserted-by":"crossref","first-page":"16923","DOI":"10.18632\/oncotarget.7850","volume":"7","author":"X Meng","year":"2016","unstructured":"Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7:16923\u201335.","journal-title":"Oncotarget"},{"key":"4974_CR22","doi-asserted-by":"publisher","first-page":"89811","DOI":"10.18632\/oncotarget.20688","volume":"8","author":"A Yokoi","year":"2017","unstructured":"Yokoi A, Yoshioka Y, Hirakawa A, Yamamoto Y, Ishikawa M, Ikeda SI, et al. A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget. 2017;8:89811\u201323.","journal-title":"Oncotarget"},{"key":"4974_CR23","doi-asserted-by":"crossref","first-page":"78095","DOI":"10.18632\/oncotarget.12947","volume":"7","author":"X Si","year":"2016","unstructured":"Si X, Zhang X, Hao X, Li Y, Chen Z, Ding Y, et al. Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. Oncotarget. 2016;7:78095\u2013109.","journal-title":"Oncotarget"},{"key":"4974_CR24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3748\/wjg.v24.i11.1206","volume":"24","author":"C Zhang","year":"2018","unstructured":"Zhang C, Zhang CD, Ma MH, Dai DQ. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients. World J Gastroenterol. 2018;24:1206\u201315.","journal-title":"World J Gastroenterol"},{"key":"4974_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-2490-14-50","volume":"14","author":"Y Feng","year":"2014","unstructured":"Feng Y, Kang Y, He Y, Liu J, Liang B, Yang P, Yu Z. microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. BMC Urol. 2014;14:50.","journal-title":"BMC Urol"},{"key":"4974_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12282-017-0814-8","volume":"25","author":"M Adhami","year":"2018","unstructured":"Adhami M, Haghdoost AA, Sadeghi B, Malekpour Afshar R. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2018;25:198\u2013205.","journal-title":"Breast Cancer"},{"key":"4974_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc2067","volume":"7","author":"A Albini","year":"2007","unstructured":"Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139\u201347.","journal-title":"Nat Rev Cancer"},{"key":"4974_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2016.03.036","volume":"142","author":"KD Dorayappan","year":"2016","unstructured":"Dorayappan KD, Wallbillich JJ, Cohn DE, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 2016;142:199\u2013205.","journal-title":"Gynecol Oncol"},{"key":"4974_CR29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3892\/ijo.2017.3948","volume":"50","author":"C Palma Flores","year":"2017","unstructured":"Palma Flores C, Garcia-Vazquez R, Gallardo Rincon D, Ruiz-Garcia E, Astudillo de la Vega H, Marchat LA, et al. MicroRNAs driving invasion and metastasis in ovarian cancer: opportunities for translational medicine (review). Int J Oncol. 2017;50:1461\u201376.","journal-title":"Int J Oncol"},{"key":"4974_CR30","doi-asserted-by":"publisher","first-page":"11150","DOI":"10.1038\/ncomms11150","volume":"7","author":"CL Au Yeung","year":"2016","unstructured":"Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150.","journal-title":"Nat Commun"},{"key":"4974_CR31","doi-asserted-by":"publisher","first-page":"e92099","DOI":"10.1371\/journal.pone.0092099","volume":"9","author":"Y Hu","year":"2014","unstructured":"Hu Y, Zhu Q, Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS One. 2014;9:e92099.","journal-title":"PLoS One"},{"key":"4974_CR32","doi-asserted-by":"publisher","first-page":"e31032","DOI":"10.1371\/journal.pone.0031032","volume":"7","author":"G Turcatel","year":"2012","unstructured":"Turcatel G, Rubin N, El-Hashash A, Warburton D. MIR-99a and MIR-99b modulate TGF-beta induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLoS One. 2012;7:e31032.","journal-title":"PLoS One"},{"key":"4974_CR33","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1172\/JCI74778","volume":"124","author":"HA Kenny","year":"2014","unstructured":"Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014;124:4614\u201328.","journal-title":"J Clin Invest"},{"key":"4974_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000152941","volume":"29","author":"L Heyman","year":"2008","unstructured":"Heyman L, Kellouche S, Fernandes J, Dutoit S, Poulain L, Carreiras F. Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol. 2008;29:231\u201344.","journal-title":"Tumour Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4974-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T18:24:09Z","timestamp":1605378249000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4974-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4974"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4974-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"assertion":[{"value":"4 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Osaka University Graduate School of Medicine approved the study protocol (# 10064). Written informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1065"}}